Pregnant women and infants are at an increased risk of severe COVID-19 infections but recent research from University of Haifa and Hadassah-Hebrew University Medical Center in Jerusalem, shows that vaccinating pregnant women early on in the third trimester may maximize transplacental antibody transfer, potentially helping to prevent severe illness in the mother and her baby.
The study found that maternal immunization with the Pfizer-BioNTech’s COVID-19 vaccine in 27-31 weeks of pregnancy was associated with higher neonatal levels of anti-SARS-CoV-2 antibodies and serum neutralizing activity than immunization during the late-third trimester (32-36 weeks). Read more